Table 1 Scope of the economic analysis
From: Cost-utility analysis of genomic profiling in early breast cancer in Colombia
Element economic analysis | Description |
|---|---|
Population | Women with HR + and HER2– early-stage breast cancer (LN0) with high-risk clinical criteria as per the MINDACT trial [19] |
Interventions | 1→Oncotype DX (cutoff points as per the TAILORx trial) [23] 2→Mammaprint (cutoff points as per the MINDACT trial) [19] |
Comparator | Chemotherapy for all |
Primary health economic outcome | Incremental cost per QALY gained and net monetary benefit |
Perspective | Colombian NHS |
Time horizon | 5 years |
Discount rate | 5% per annum. A sensitivity analysis was performed with discount rates of 0%, 3.5%, and 7% [24] |
Price year | 2021 |